Are drug-eluting stents superior to bare metal stents when compared to coronary artery bypass surgery? Show me the data

Cardiovascular Revascularization Medicine

Volumn 14, Issue 2, 2013, Pages 90-92

  Rodriguez, Alfredo E ^a  

^a Sanatorio Otamendi y Miroli   (Argentina)

Author keywords

Bare metal stents; Coronary artery bypass surgery; Coronary artery disease; Drug eluting stents; Randomized trials

Indexed keywords

ARTICLE; BARE METAL STENT; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; INCIDENCE; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VASCULAR DISEASE;

CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875063116     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2012.11.002     Document Type: Article

References (19)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780. RAVEL Study Group.
2. Moses J.W., Leon M.B., Popma J.J., SIRIUS Investigators, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
3. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we cautious?. Circulation 2004, 109:701-705.
4. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005, 46:231-236.
5. MacFadden E.P., Stabile E., Regar E., et al. Late stent thrombosis in drug-eluting coronary stent after discontinuation of antiplatelet therapy. Lancet 2004, 364:1419-1421.
6. Rodriguez A.E., Mieres J., Fernandez-Pereira C., et al. Coronary stent thrombosis in the current drug-eluting stent era: Insights from the ERACI III trial. J Am Coll Cardiol 2006, 47:205-207.
7. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007, 50:501.
8. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metaltents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
9. Taggart D. Sintax five years 2012.
10. Farkouh M.E., Domansky M., Sleeper L.A., et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012, 10.1056/NEJMoa1211585.
11. Hlatky M.A., Boothroyd D.B., Bravata D.M., et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009, 373:1190-1197.
12. Daemen J., Boersma E., Flather M., et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008, 118:1146-1154.
13. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009, 360:961-972.
14. Rodriguez A.E., Maree A.O., Mieres J., et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J 2007, 28:2118-2125.
15. Lagerqvist B., James S.K., Stenestrand U., Lindbäck J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019. for the SCAAR Study Group.
16. Caixeta A., Leon M.B., Lansky A.J., et al. 5-year clinical outcomes after sirolimus eluting stent implantation: Insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009, 54:894-902.
17. Stone G., Ellis A., Colombo A., et al. Long term safety and efficacy of paclitaxel eluting stents. Am Coll Cardiol Intv 2011, 4:530-542.
18. Claessen B.E., Stone G.W., Smits P.C., et al. Would SYNTAX have been a positive trial if XIENCE V have been used instead TAXUS? A meta analysis of a first-generation vs a second generation drug-eluting system. Neth Heart J 2010, 18:451-453.
19. Caixeta A., Lansky A.J., Serruys P.W., et al. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovasc Interv 2010, 3:1220-1228.